Thomas Steyer’s Editas Medicine EDIT Stock Holding History

Thomas Steyer’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-515,000	Closed	-$15.8M	–	94
2017 Q4	$15.8M	Buy	+515,000	New	+$13M	0.13%	59

Other funds holding EDIT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Thomas Steyer's EDIT Position: Q1 2018 in Review

Thomas Steyer sold out of Editas Medicine (EDIT) in Q1 2018, closing a stake of 515,000 shares — an estimated $15.8M sold.

Thomas Steyer first reported a position in EDIT in Q4 2017 and held it in 1 quarter. The position peaked at $15.8M in Q4 2017. 197 funds tracked by Wall St. Rank hold EDIT as of Q1 2018.

Thomas Steyer reported no remaining Editas Medicine position as of Q1 2018 after selling out during the quarter.
Thomas Steyer sold 515,000 Editas Medicine shares in Q1 2018, an estimated $15.8M.
Thomas Steyer first reported a position in Editas Medicine in Q4 2017 and held it in 1 quarter.
Thomas Steyer's Editas Medicine position peaked at $15.8M in Q4 2017.
197 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2018.

Based on Farallon Capital Management's 13F filing for Q1 2018, filed 15 May 2018.